Description:
A substance being studied in the treatment of advanced pancreatic cancer. Yttrium Y 90-clivatuzumab tetraxetan contains a monoclonal antibody that binds to a protein called MUC-1, which is found on some pancreatic cancer cells. It also contains a radioactive substance called yttrium Y 90, which may help kill cancer cells. Yttrium Y 90-clivatuzumab tetraxetan is a type of radioimmunoconjugate. Also called yttrium Y 90-DOTA monoclonal antibody HuPAM4.
